To this aim , we designed an efficient technology
relying on two discrete and sequential steps :
To this aim , we designed an efficient technology relying on two discrete and sequential steps : first , human B - lymphocytes are stimulated with TLR9-agonists and IL-2 ; second , after both additives are removed , the cells are infected with EBV .
To this aim , we designed an efficient technology relying on two discrete and sequential steps : first , human B - lymphocytes are stimulated with TLR9-agonists and IL-2 ; second , after both additives are removed , the cells are infected with EBV .